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Abstract
A significant amount of complexity exists within the brand and product portfolios of
PharmaCo. This complexity is driven by several factors: first, medical needs for differing
products and dosages; second, marketing requests for new configurations of current product
offerings; third, unique regulations and requirements for individual country markets; fourth,
product portfolio growth from acquisition activity. This complexity increases both
production costs and support costs (such as planning and procurement) for PharmaCo. The
focus of this project is to reduce the complexity in the brand and SKU portfolios at
PharmaCo.
Two approaches can be utilized to reduce complexity in the product portfolio. First,
measures can be taken to reduce already existing SKUs and brands. This has largely been
the focus of previous efforts at PharmaCo, although additional work remains in this area.
Previous analyses have focused on providing recommendations for pruning specific SKUs
and divesting or pruning specific brands. Second, measures can be taken to manage the
future proliferation of SKUs and brands in order to control future complexity growth. This
approach has been largely unaddressed in previous internship projects and will be a major
focus of the current project.
It is first necessary to clearly understand all costs that are associated with complexity.
Consequently, the first step of this project was to conduct site visits with multiple plants in
order to learn all costs that are impacted by complexity. At these site visits, cross functional
groups involved in all aspects of operations at the site were identified and consulted.
Additionally, Marketing was contacted to understand complexity costs that affect
Marketing. Both cost elements will be combined to develop a complexity cost model. This
model is being piloted and applied to a stable brand that still has level or increasing volumes
over the next several years.
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Thesis Supervisor: Roy Welsch
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3
This page intentionally left blank
4
Acknowledgments
I would like to acknowledge Don Rosenfield and the Leaders for Global Operations
Program for the support, insight, and guidance that have been offered throughout this
project. I would also like to thank my advisors, Roy Welsch and Debbie Nightingale, for
supporting this research. Their advice and oversight was invaluable in completing this work.
I would like to thank my supervisor and colleagues at PharmaCo. These individuals have
offered incredible support and help. They have been completely open and welcoming and
their involvement has been essential to this work.
Finally and most importantly, I would like to thank my wife, Liz. Without her support and
patience, none of this would have been possible.
5
This page intentionally left blank
6
Table of Contents
A b stract .................................................................................................................................... 3
Acknowledgm ents....................................................................................................................5
Table of Contents ..................................................................................................................... 7
List of Figures ........................................................................................................................ 10
1 Introduction......................................................................................................................11
1.1 Trends in the Pharmaceutical Industry ................................................................. 11
1.2 Pharm aCo .................................................................................................................. 12
1.3 M otivation and Problem Statement ........................................................................... 13
1.4 Hypothesis ................................................................................................................. 13
1.5 Thesis Outline............................................................................................................13
2 Literature Review ............................................................................................................. 15
3 Complexity Drivers ...................................................................................................... 20
3.1 Lifecycle Activities Complexity.............................................................................20
3.1.1 Launch.................................................................................................................20
3.1.2 Local M anufacturing...................................................................................... 21
3.1.3 Site and Supplier Consolidation...................................................................... 22
3.1.4 Brand and SKU Elim ination .......................................................................... 22
7
3.1.5 D ivestm ent ...................................................................................................... 23
3.1.6 Licensing-in ................................................................................................... 24
3.1.7 Co-m arketing ................................................................................................... 24
3.2 Business M odel Com plexity.................................................................................. 25
3.2.1 Final Drug D elivery Form ............................................................................... 25
3.2.2 D osage Level ................................................................................................... 26
3.2.3 Sales Channel................................................................................................. 26
3.2.4 Business U nit A utonom y............................................................................... 27
3.2.5 V aried M arkets and G eographies.................................................................... 27
3.2.6 Legacy Products............................................................................................. 28
3.2.7 Products W ith Special Requirem ents............................................................. 28
3.2.8 Representative Example of Complexity Proliferation .................................... 28
4 Com plexity Cost M odels............................................................................................... 30
4.1 Bottom -up Com plexity Cost M odel...................................................................... 30
4.1.1 A pproach.............................................................................................................30
4.1.2 Site V isit..............................................................................................................32
4.1.3 Results and Outcom e ..................................................................................... 33
8
4.2 Top-down Complexity Cost M odel...................................................................... 35
4.2.1 Approach.............................................................................................................35
4.2.2 A ssum ptions.................................................................................................... 37
4.2.3 M odel..................................................................................................................41
4.2.4 Results.................................................................................................................41
5 Case Study - Safety Stock Holding Costs ................................................................... 47
5.1 Business Unit SKU Reduction Pilot ...................................................................... 47
5.2 Approach ................................................................................................................... 49
5.2.1 The Square-root Rule ...................................................................................... 50
5.2.2 Classic Inventory M anagement M odel........................................................... 51
5.3 Results ....................................................................................................................... 53
6 Conclusion........................................................................................................................56
6.1 N ext Steps and Further W ork ............................................................................... 57
Appendix ................................................................................................................................ 59
References .............................................................................................................................. 61
9
List of Figures
Figure 1: Wilson and Perumal's framework for managing complexity[2].........................15
Figure 2: Collinson and Jay's complexity curve[3]. ......................................................... 16
Figure 3: Anderson, Hagen, and Reifel's root causes of complexity[5].............................18
Figure 4: Anderson, Hagen, and Reifel's approach to a component-based portfolio[5]........19
Figure 5: Complexity drivers and product offering proliferation. .................................... 29
Figure 6: Bottom-up complexity cost model approach......................................................31
Figure 7: Mapping of complexity cost drivers to resources and activities.........................32
Figure 8: Top-down complexity cost model approach......................................................37
Figure 9: Comparison of single-SKU and multi-SKU cost model assumptions...............41
Figure 10: Complexity costs derived from top-down model. ........................................... 42
Figure 11: Complexity cost breakdown (proportional)......................................................42
Figure 12: Comparison of production batches required (normalized to scale of 100).....43
Figure 13: Comparison of required machinery (normalized to scale of 100)...................43
Figure 14: Comparison of required labor (normalized to scale of 100).............................44
Figure 15: Comparison of required material costs (normalized to scale of 100)..............45
Figure 16: Comparison of non-labor and non-material costs (normalized to scale of 100)...46
Figure 17: SKU reduction pilot for Country X business unit ............................................ 48
Figure 18: Reduction in safety stock holding costs due to SKU consolidation. ................ 54
Figure 19: Safety stock holding cost reduction to consolidated SKU pairs.......................55
Figure 20: Plant granulation, tabletting, and coating layout. ............................................. 59
Figure 21: Plant packaging layout...................................................................................... 59
Figure 22: Packaging line overview .................................................................................... 60
10
1 Introduction
1.1 Trends in the Pharmaceutical Industry
The pharmaceutical industry as a whole has been very profitable over the past
several decades. However, this profitability is increasingly coming under pressure. As a
result, major players in the industry are increasingly looking for ways to manage costs and
maintain profitability.
Expiring patents and the introduction of new generic competitors have contributed to
the pressure on profitability for major pharmaceutical companies. In 2000, generics
comprised 49% of market share. By 2011, generics are estimated to have been 80% of
market share in the pharmaceutical industry[1]. Generic drug introduction typically
decreases prices significantly, often driving margins for a specific drug to a fraction of the
level before generic drug introduction.
The industry is also marked by very high R&D costs and relatively large amounts of
intangible assets. The intangible assets typically take the form of patents or intellectual
property (IP). Industry-wide R&D spending exceeded $50 billion in 2010 and typically
represents 17% of revenues for major pharmaceutical companies [1]. The cost to develop a
new drug currently stands at $1.2 billion and typically takes 10 to 15 years [1]. Companies
in the industry are increasingly competing by investing in increasingly expensive drug
development pipelines.
These factors are expected to continue to play a role in putting pressure on
profitability in the coming years. Other factors, such as legislation, also may play a large
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role. For these reasons, companies in the industry are increasingly looking for ways to
reduce costs and maintain or improve profitability.
1.2 PharmaCo
PharmaCo is a major pharmaceutical company with operations across the world.
PharmaCo manufactures drugs for both prescription and over-the-counter uses, although a
large majority of PharmaCo's products are intended for prescription use. PharmaCo also
operates in adjacent businesses, such as biopharmaceuticals and vaccines, that complement
the company's core strengths in the chemical-based pharmaceutical sector.
PharmaCo is an industry leader in many functional areas. PharmaCo is particularly
strong in operational capabilities and quality control. PharmaCo operates manufacturing
facilities in geographies spread across the world and sells products in over 100 countries.
PharmaCo is a leader in many product sectors, such as oncology and hypertension.
PharmaCo sells products through a variety of channels with the primary channels being
hospitals, pharmacies, and government agencies.
PharmaCo has experienced rapid growth for much of its history, especially in the
recent past. This growth has helped PharmaCo to become a dominant entity in the industry
and allowed the company to achieve strong profitability. However, the fast pace of growth
has also caused PharmaCo to focus efforts in several different directions. Opportunities for
strengthening the company's internal operations even more certainly exist and can lead to
yet another source of market dominance.
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1.3 Motivation and Problem Statement
In response to industry trends and in an effort to maximize profitability, PharmaCo
has implemented a very successful program of operational excellence over the last several
years. This program has materialized in a variety of forms, from shop-floor Lean projects to
supply chain optimization. These efforts have led PharmaCo to analyze the composition of
their product portfolio. PharmaCo has determined that the company's product portfolio has
grown tremendously in the last several years. This has led to a conclusion that the complex
product portfolio may not be optimally profitable. Complexity in the product portfolio
creates many additional costs, some of which are not obvious under the current reporting
systems. As a result, PharmaCo has initiated an effort to identify and manage complexity in
the product portfolio.
1.4 Hypothesis
We propose that complexity costs caused by the varied product portfolio at
PharmaCo are significant but can be managed. We propose that these complexity costs can
be identified through development of a complexity cost model and that consolidation of
product offerings can provide valuable cost savings to the organization.
1.5 Thesis Outline
In Chapter 2, we conduct a brief review of the literature and work that has been done
concerning complexity management. A large portion of this work concerns complexity
management for a variety of industries but is applicable to our case in the pharmaceutical
industry.
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In Chapter 3, we perform an analysis of the key drivers of complexity at PharmaCo.
These complexity drivers can be extended to the general pharmaceutical industry.
In Chapter 4, we present two approaches to developing complexity cost models. The
output of the latter model is also presented.
In Chapter 5, we present a case study of a pilot program to consolidate product
offerings in one of PharmaCo's business units. This effort to reduce complexity
demonstrates the benefits of managing complexity in the product portfolio.
In Chapter 6, we present our conclusions, key findings, and suggestions for future
work.
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2 Literature Review
Wilson and Perumal describe three types of complexity: product complexity, process
complexity, and organizational complexity[2]. Product complexity arises from the variety of
products and services that a company offers. Process complexity arises from the work
required to maintain and offer product complexity, such as rework, coordination, and
redundant production processes for slightly different customers. Organizational complexity
arises from features of the organizational structure that are required to support product
complexity, such as staffing, assets, and multiple production sites.
Wilson and Perumal also propose a framework for dealing with complexity[2]. This
framework includes two approaches, as shown in Figure 1 below: either reduce the amount
of complexity or make complexity less expensive.
Reduce Make complexityamount of -es e xpensive
complexity E EE
Figure 1: Wilson and Perumal's framework for managing complexity[2].
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Collinson and Jay have explored the nature of complexity and how it affects the
profitability of an organization[3]. They break complexity into two categories: good
complexity and bad complexity. Through their research, they have developed an index to
classify companies according to their complexity. This has led to Figure 2 below. Collinson
and Jay state that there is a tipping point, after which complexity works against improved
performance and profitability of the overall organization[3]. They also point out that in the
pharmaceutical industry, increased pressure for consolidation has driven a significant
amount of merger and acquisition activity. This in turn leaves companies in the industry
with the added challenge of integrating an acquired organization into the parent
organization. This compounds complexity. This is further compounded by intense research
and development (R&D) spending, vast and disconnected operating units, and over-
engineering of processes. This in turn causes more complexity, disjointed coordination
between operating units, and strategic misalignment.
Profit
(EBITDA)
= 10.2%
U
U
U
U
GOOD COMPLEXITY BAD COMPLEXITY
Improves your performance Increases cost and destroys value
Complexity
Figure 2: Collinson and Jay's complexity curve[3].
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Wilson and Perumal further propose that bad complexity (for example, extra
production planning due to offering nearly-identical products) should be eliminated and that
good complexity (for example, offering two different brands that cater to different customer
needs) should be made less expensive. Thus, methods to the left of Figure 1 can be used to
attack bad complexity and methods to the right of Figure 1 can be used to attack good
complexity.
Byrne prescribes a three-pronged approach to dealing with complexity[4]: first, study
products from the consumer's point of view in an effort to identify those worth keeping;
second, identify SKUs that serve unique channels; third, execute an initiative to eliminate
products that have failed to meet customers' needs or achieve a minimum threshold of
demand. Byrne argues that companies often implement these three approaches individually.
However, he shows that it is necessary to implement the three approaches together to
achieve lasting and impactful complexity reduction.
Byrne also points out that consolidating a product portfolio to reduce complexity
often focuses on cutting (also termed pruning) the lowest-volume SKUs. For example, a
company will often dictate that the 5% of lowest demand SKUs be pruned. Byrne, however,
states that this will yield very meager results in improving profitability because these SKUs
have such limited volume that their elimination does very little to change the dynamics of
the product portfolio. Rather, Byrne states that effective complexity reduction programs
must focus on SKUs in the middle of the volume curve[4]. Carefully designed and executed
efforts focusing on these higher volume SKUs have the potential to achieve significant and
lasting complexity reductions that will improve profitability.
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Anderson, Hagen, and Reifel document the root causes of complexity as well as the
tradeoffs between complexity and customization[5]. They describe complexity as the result
of several isolated decisions, all made with the intention of winning the customer by offering
customized products. However, these decisions unintentionally create a complex system of
increased operating costs, new processes, and inefficient practices. Figure 3 below shows
their description of the root causes of complexity.
oii le it
Source: A. T Keamey I-.-!
Figure 3: Anderson, Hagen, and Reifel's root causes of complexity[5].
Anderson, Hagen, Reifel discuss modifying a company's system so as to create a
simplified and component-based product portfolio[5]. This starts by locating complexity in
the organizations and then modifying the way that customization is introduced into the
product portfolio to create component-based offerings. Their representation of the
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relationship between the component-based product portfolio and profitability is shown in
Figure 4 below.
Adjust complexity of the offering
once component-based systems
and processes are in place
New products ystems
and processes
Current product offering,
systems and processes
Develop
component-based
products, systems
Elimmate and processes
destroy value
Current product Product variety
Source: A T Kearney or service offering
Figure 4: Anderson, Hagen, and Reifel's approach to a component-based portfolio[5].
With this understanding of the previous work on complexity management, we move
on to an analysis of the drivers of complexity at PharmaCo.
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3 Complexity Drivers
In order to develop a better understanding of complexity costs at PharmaCo, a study of
the underlying causes and drivers of complexity in the product portfolio was undertaken.
These complexity drivers can be viewed from two different perspectives: complexity arising
from product lifecycle activities or complexity arising from the structure of PharmaCo's
business model. Both of these perspectives will be considered. Understanding how these
drivers create and contribute to complexity in PharmaCo's product portfolio will be valuable
in developing a complexity cost model.
3.1 Lifecycle Activities Complexity
When considering lifecycle activities, it is important to note that, in addition to the
level of complexity, these activities may also affect the profitability, growth, and cost of
goods sold (COGS) of the overall product portfolio. The following primary lifecycle
activities were identified as having the largest effect on complexity.
3.1.1 Launch
Launching a new product increases the overall complexity in the product portfolio.
This is simply a result of at least one new SKU being generated in the company's system
and often, a newly launched product can result in several new SKUs (for example,
corresponding to different dosage levels or varying package configurations). A new product
offering also often requires new production processes on the factory floor and, in some
cases, new processing equipment. This also increases production complexity associated with
the new product offering. Under normal circumstances, launching a new product should
positively affect overall company growth as the new product offering captures new
customers. Profitability (in an absolute sense) should generally be affected positively by
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launching a new product; it may be the case that hidden complexity costs make a new
product less profitable than anticipated, but the general effect from a new product should be
at least positive as a business case justifying the launch is required before introduction.
Finally, the ratio of cost of goods sold (COGS) in the product portfolio could be affected
negatively or positively depending on whether the new product is more or less profitable
than the current aggregate product portfolio.
3.1.2 Local Manufacturing
Manufacturing products locally refers to production that occurs in close proximity to
the end user. Often this arises from requirements by a government or regulatory body that
the pharmaceutical company manufactures in the region or country where the products will
be sold. However, this can also be driven by a desire to react quickly to local market needs
or to more fully tailor production of a product to local market preferences. Local
manufacturing almost certainly increases complexity in the production system of PharmaCo.
Local manufacturing often requires a new site, a significant factor in increasing complexity.
A technology and process transfer to the new site must also take place, both of which can be
very complicated tasks. A new drug product variant is required for a new local site.
Additionally, establishing a new local site, particularly in an area that PharmaCo has not
previously operated in, introduces an increased risk for quality and compliance issues. It is
unclear whether local manufacturing will increase or decrease overall profitability (in an
absolute sense) due to the many factors and costs detailed above; in some cases, PharmaCo
may produce products locally with a negative margin in order to gain access to a strategic
market. However, local manufacturing will typically have the effect of increasing growth of
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overall products sales as the new markets are served. Finally, local manufacturing will
almost always increase the overall COGS ratio of the entire product portfolio.
3.1.3 Site and Supplier Consolidation
Initiatives to reduce the number of production sites that PharmaCo operates have
become increasingly more common. In these cases, it is assumed that total production
volumes will remain constant and not decrease. Consolidating production sites in this
manner increases the utilization of capital equipment and often eliminates multiple
manufacturing locations for a given drug, thereby reducing end-product variation. These
efforts to consolidate manufacturing sites decrease the total complexity in the production
system. Similarly, initiatives to reduce the number of suppliers also reduce complexity by
simplifying sourcing operations and reducing variability from multiple sources. These
consolidation efforts, under the assumption that volumes are simply transferred and not
reduced, results in no effect on overall growth of sales volumes. Overall profitability (in
absolute terms) is increased as overhead costs are reduced and redundancies in operations
are eliminated. Additionally, the overall COGS ratio of the product portfolio is improved as
the direct costs of manufacturing and sourcing are streamlined.
3.1.4 Brand and SKU Elimination
Brand elimination, also known as pruning, represents an initiative whereby entire
brands are discontinued and cut out of the product portfolio. This can be done at a more
focused SKU level, but eliminating entire brands results in larger impacts on complexity,
profitability, growth, and the COGS ratio. SKUs or brands can be eliminated for a variety of
reasons, including low demand volumes, remaining remnants from acquisition activity that
fit poorly in the product portfolio, or a changing strategic or competitive landscape. When a
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SKU or entire brand is pruned, the overall complexity of the product portfolio decreases as
there are fewer SKUs being produced in the portfolio. Growth of overall sales revenue is
decreased as it is assumed that the demand for the pruned SKUs is not necessarily
transferred to other existing SKUs. Overall profitability (in absolute terms) can either
increase or decrease, depending on the margins of the SKUs or brand being eliminated. It is
reasonable to expect that some pruning candidates will have negative margins as volumes
have decreased, causing the SKUs or brand in questions to have been identified for pruning.
Similar to profitability, the overall COGS ratio of the entire product portfolio can also
increase or decrease depending on the characteristics of the SKUs or brand being pruned.
3.1.5 Divestment
The impacts of divestment activities are very similar to those of brand elimination
activities. However, in divestment initiatives the SKUs or brands that are identified are sold
to other entities instead of simply being discontinued. Here also, individual SKUs or entire
brands can be divested, although entire brands are much more common as an individual
SKU would have to fit into the new entity's production and product offering systems.
Divestment decisions must be evaluated carefully so as to avoid giving away strategic or
competitive advantages to other entities. Divestment activities will decrease the amount of
complexity in the production system and product portfolio as the number of SKUs in
PharmaCo's portfolio is being directly reduced. Growth of revenue will decrease as it is
assumed that the volumes of the divested products are not being transferred to another
existing SKU or brand. The overall profitability (in absolute terms) of the product portfolio
may increase or decrease, depending on the margins of the SKUs being divested. Similarly,
the COGS ratio of the entire product portfolio may also increase or decrease depending on
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whether the COGS ratio of the divested SKUs is higher or lower than that of the entire
portfolio.
3.1.6 Licensing-in
In some circumstances PharmaCo may seek to obtain licensing rights from another
company for a particular product or brand. This activity is very common in the industry as
patents and IP play such an important and long-term role. Licensing-in new products will
typically require PharmaCo to create and maintain a new internal brand along with
associated SKUs, increasing overall complexity in the production system. In some cases, a
new production site may be required; at the very least, new processes will be required. These
factors both also increase complexity in the production system and the product portfolio.
Growth of overall sales revenues is increased as the new products capture new customers.
Overall profitability (in absolute terms) increases as it is assumed the PharmaCo will only
license-in new products that will realize a positive profit margin. The impact on the overall
COGS ratio of the product portfolio may increase or decrease, depending on whether the
COGS ratio of the new licensed products is higher or lower than the aggregate COGS ratio
for the entire product portfolio.
3.1.7 Co-marketing
Co-marketing arises when PharmaCo partners with another party in an agreement to
utilize the partner's sales and marketing force to sell PharmaCo's products. This often arises
when PharmaCo doesn't have a strong presence in a particular market or geography but the
partner does. This allows PharmaCo to still generate revenue and sales without making the
investments required to establish its own sales and marketing operations in the given
location. Additionally, the co-marketing partner often has key relationships with customers
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or regulatory bodies in the target market. Co-marketing increases complexity in the product
portfolio due to the new SKUs and product packaging that must be generated in order to sell
into the new target market. Growth of overall sales revenues will increase as new customers
are captured that were previously not purchasing PharmaCo products in the target market.
Overall profitability (in absolute terms) will increase as new profitable sales are generated.
The impact of the overall COGS ratio of the product portfolio will increase; this occurs
because the new co-marketed SKU starts with a COGS ratio that is similar to that of the
existing SKU sold directly by PharmaCo but then adds costs related to the revenue sharing
agreement with the co-marketing partner in the target market.
3.2 Business Model Complexity
Several aspects of the products that PharmaCo offers and the way that PharmaCo
structures its business operations contribute to complexity within the product portfolio. This
complexity affects both the size and scope of the portfolio itself as well as the underlying
production systems and costs. As a result, it is important to understand the key aspects that
drive complexity, especially if a complexity cost model is to be constructed.
Complexity due to the business model is driven by several factors: the final drug
delivery form, the dosage level, the sales channel, autonomous PharmaCo business units,
varied markets and geographies that PharmaCo serves, legacy products from acquisition or
divestment activities, and special requirements preventing the phasing-out of certain
products. In general, all of these aspects increase complexity in the product portfolio and in
the production systems.
3.2.1 Final Drug Delivery Form
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In many cases, PharmaCo offers a given drug product in several different final
delivery forms. PharmaCo's products can take the form of tablets, sprays, gels, capsules,
syrups, creams, and a variety of other possibilities. Offering the same drug in various final
delivery forms requires additional manufacturing processes, additional packaging processes,
an increased number of substances from suppliers, and additional SKUs. Additionally, even
if multiple final delivery forms for a single drug product are neglected, multiple final
delivery forms for different drug products still require different manufacturing equipment,
suppliers, and production processes.
3.2.2 Dosage Level
For a given drug in a given final drug delivery from, PharmaCo often offers multiple
dosage levels. For example, PharmaCo may produce and offer a drug in tablet form in
50mg, 100mg, and 150mg dosage levels. These different dosage levels are sometimes
required by regulation and sometimes offered to meet customers' desire for flexibility in
dosing. Multiple dosage levels require unique SKUs, unique packaging (typically), and
separate production processes. All of these factors increase complexity.
3.2.3 Sales Channel
PharmaCo offers its products through many different channels. For example,
products may be sold to hospitals, pharmacies, or clinics. The different channels often
require different pricing and packaging. Additionally, channels such as hospitals are often
offered samples packs, typically consisting of a few dosages. These sample packs are
intended to be used as an introductory trial by doctors in order to secure new customers.
These considerations usually require separate SKUs (and often unique production
processes), increasing complexity.
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3.2.4 Business Unit Autonomy
PharmaCo is a large company but makes efforts to operate as a flat organization in
many respects. Accordingly, PharmaCo gives its business units (which are often organized
by country) a large amount of autonomy in planning product offerings and making decisions
to launch new products. While this model certainly has many advantages, it can often lead to
a wide variety of similar but different products being offered across country business units.
For example, the France business unit may decide that customers in France will respond
most favorably to Drug X when it is offered in a 4x5 blister pack, while the Germany
business unit may decide that customers in Germany will respond most favorably to Drug X
when it is offered in a 3x7 blister pack. This phenomenon, when spread across business units
all over the world and across hundreds of different drug products, can result in a significant
number of similar but different SKUs in the overall product portfolio. This increases
complexity very rapidly.
3.2.5 Varied Markets and Geographies
PharmaCo is a global company and, as such, operates in numerous markets spread
out all over the world. The size of the markets range from some of the largest countries in
the world to much smaller, localized geographies. Often, these markets have unique
regulatory agencies and requirements for pharmaceutical products. These varying
regulations can require different packaging, process control, and supplier selection. All of
these factors require unique SKUs for products of the same drug brand that will be sold in
the different markets, increasing complexity in the product portfolio and production systems.
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3.2.6 Legacy Products
PharmaCo has acquired many other entities and divested many brands over the
course of its history. During acquisitions, PharmaCo sometimes obtains products that were
not the primary target and do not fit particularly well in PharmaCo's product portfolio.
Similarly, during divestments, PharmaCo may be left with a few products or SKUs that no
longer fit particularly well in the product portfolio. Over time, PharmaCo has accumulated a
number of SKUs and brands with low volumes and little strategic fit, increasing the
complexity within the product portfolio and production system.
3.2.7 Products With Special Requirements
Finally, there are certain products that PharmaCo produces that the company must
continue to produce, regardless of demand volumes and profitability. The most common
case of this occurs when PharmaCo produces a drug for which there is a stipulated medical
need by regulatory authorities and PharmaCo is obligated to continue to supply this drug.
PharmaCo often agrees to supply these medical need drugs as a condition of gaining access
to a market for another drug or product. These medical need drugs often become
unprofitable, especially when volumes for them are low, which can often be the case. They
also require SKUs, production processes, and distribution, all of which add complexity to
PharmaCo's product portfolio and production systems.
3.2.8 Representative Example of Complexity Proliferation
Figure 5 below shows how some of the complexity drivers described in this section
can cause complexity to increase very quickly in the product portfolio. In this example,
different dosage levels, pack configurations, and target market packaging requirements
contribute to the SKU proliferation from a single drug product. However, any of the other
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complexity drivers described in this section could similarly cause an increase in the product
portfolio complexity. This simple example indicates the vast scale of complexity at
PharmaCo across scores of different drug products and brands.
I I7
3 Dosage 9 Tooling 22 Pack
Levels Setups Configurations
2ffiJ
220 Unique SKUs
Figure 5: Complexity drivers and product offering proliferation.
In the next chapter, we use this understanding of the complexity drivers at PharmaCo
to develop a complexity cost model.
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4 Complexity Cost Models
The first step in devising a strategy to deal with complexity in the product portfolio
and the production system is to understand the scale of complexity at PharmaCo.
Additionally, it is important to understand what products and activities are contributing the
most to complexity and the associated costs. In order to address this, an initiative to develop
a complexity cost model has been undertaken.
4.1 Bottom-up Complexity Cost Model
The first effort to construct a complexity cost model focused on a bottom-up
approach, starting from an individual SKU at a plant level.
4.1.1 Approach
The key premise underlying the bottom-up cost model is to consider how complexity
is affected by creating a single, new SKU in the product portfolio. The intent is to determine
every activity that must occur in order to create the new SKU and to map appropriate costs
to each of these activities.
Due to the way that cost accounting is employed at PharmaCo, there are many
indirect costs related to creating a new SKU that may not be directly allocated to the SKU's
costs. The primary costs allocated to a new SKU (and included in the business planning
process) are direct labor and material costs for production. Costs related to new capital
equipment that is required and marketing costs related to the product launch may also be
included. However, production costs related to additional equipment changeovers and setups
are typically not included. Additionally, time and labor required by planners, material
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purchasers, lifecycle managers, brand managers, and other supporting agents are typically
not included in the costs required to launch and maintain a new SKU.
In order to clearly understand and evaluate all activities related to creating a new
SKU, a site visit was planned. At the site visit, meetings were arranged with all functional
groups that could be affected by the creation of a new SKU. This included plant
management, production planners, production supervisors, material purchasers, packaging
artwork managers, sales and marketing staff, lean manufacturing project leaders, financial
analysts, and a variety of other functional representatives.
A large motivation behind making this effort to understand all costs associated with
creating and maintaining a new SKU in the product portfolio is the desire to determine some
cost metric to represent complexity for future business planning. It was anticipated that there
would be some variation in the different tasks required to create SKUs in different scenarios,
but it was hoped that the different scenarios could be aggregated to a representative cost
adjustment. This could be applied to the direct costs for new products, giving a more
representative estimate of the true costs to launch and maintain a new SKU. This would be
inclusive of costs due to complexity.
The general approach to the bottom-up complexity cost model is shown in Figure 6.
Figure 6: Bottom-up complexity cost model approach.
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4.1.2 Site Visit
At the site visit, the group including the functional representatives described above
was assembled. An exercise was first conducted to discuss the complexity cost drivers and
how they affect operations at the plant level. A key insight which holds at the plant level
became apparent: the primary cost drivers are time (i.e. setup time), number of orders
processed through a given piece of equipment in a given period of time, and inventory
generated by the operating activities. These cost drivers are affected by the resource
allocation in the plant, which in turn map to activities. The relationship between the plant-
level resources, cost drivers, and activities was mapped out in order to better understand
where the largest cost impacts might be occurring. This mapping, which is specific to the
plant-level, can be seen below in Figure 7. This shows that people should be the resource
with the widest range of impact on costs through the many activities that this resource maps
to.
Figure 7: Mapping of complexity cost drivers to resources and activities.
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Using this mapping as a guideline, a list of various basic scenarios for which new
SKUs is generated. This list primarily consisted of the following general groupings:
e New brand launch
e New market introduction (or new geography introduction) for an existing brand
" New configuration offering (e.g. 4x6 blister pack) for an exiting brand
" Packaging update (driven by either marketing or regulatory requirements)
" New sales channel offering for existing product (e.g. channel-specific packaging or
product configuration)
e New packaging format due to supplier offerings, supply chain constraints, or supplier
discounts
After generating this list of scenarios for creating a new SKU, process maps were
created of all activities required for each scenario. These process maps were broken down
into the most basic component activities possible with the associated employees that would
be affected or required to take action. Corresponding estimates of the amount of time for
each action and employee were also determined.
4.1.3 Results and Outcome
Mapping out the processes and activities for creating a new SKU under different
scenarios resulted in several key insights into understanding complexity at PharmaCo. It was
discovered that the number of activities required to create a new SKU was subject to
significant variation. Depending on the circumstances, as few as five or as many as 3,000
activities might be required to create a new SKU. Accordingly, creating a new SKU might
require only a few minutes of extra labor, or might require several days or weeks of labor
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(often spread across several months). A preliminary analysis of the distribution of the
different scenarios was equally varied, meaning that one representative set of activities and
costs corresponding to creating a new SKU is very difficult to define.
This variation causes a significant impediment to developing a bottom-up cost
model. Because the number of activities, and by extension costs, to create a new SKU vary
significantly, a single metric representing the cost of complexity for new SKUs would be
largely unrepresentative of a majority of the instances where a new SKU is created. As a
result, an approach different to the bottom-up approach must be undertaken and will be
described later.
However, the effort to develop a bottom-up approach did also yield some valuable
insights into complexity. As discussed previously, the effort led to a definition of the general
circumstances that drive the generation of new SKUs at the plant level. This is valuable for
both plant operational planning and central plant allocation planning in order to minimize
unnecessary costs and production interruptions. Additionally, the effort also led to the
development of a model to understand the relationship between resources, cost drivers, and
activities at the plant level (as shown previously). This is helping to guide decisions related
to batch sizes, order frequency, and personnel allocation.
Finally, the effort to understand new SKU generation at the plant level led to
discussions about approaches at the plant level to deal with complexity caused by a complex
product portfolio. These approaches were based on Lean manufacturing principles. The
following examples were cited:
e Changing silver foil on packaging boxes to silver ink
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e Harmonizing production to run larger batch sizes, better utilizing equipment
* Standardizing tube diameters for different product offerings of similar creams,
enabling bulk discounts on materials and higher trucking utilizations in shipping
All of these examples led to very significant cost savings at the plant level. More
importantly, these examples led to a key finding: bottom-up, SKU-level complexity
management should focus on optimizing operations through Lean principles and should be
directed at the plant level (as opposed to the division or corporate level). Significant process
savings can be realized through following this recommendation.
4.2 Top-down Complexity Cost Model
Due to the limitations of the bottom-up model, a different method of modeling the
cost due to complexity in the product portfolio was devised. This method focuses on a top-
down approach that aggregates complexity in a plant into a single bucket. While potentially
less precise than the bottom-up model, the top-down model provides a better sense of the
magnitude of complexity costs.
4.2.1 Approach
The concept of a plant that produces only a single brand and single SKU underpins
the top-down complexity model. First, consider a plant in PharmaCo's production network.
The current production costs on an annual basis are known. These production costs are the
result of producing a varied product portfolio consisting of many brands and SKUs.
The next step in building the top-down complexity cost model is to simulate what
production costs would be if only a single SKU were produced at the same plant. This
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requires an in-depth understanding of the plant being analyzed, particularly in the following
areas:
" Labor: direct operators, supervisors, and other overhead staff (such as quality
assurance, managers, production planners, accounting staff, etc.)
e Capital equipment: granulation machinery, tableting machinery, coating machinery,
and packaging machinery
e Manufacturing processes: batch sizes, setup durations and frequencies, line
changeover durations
* Material requirements: purchasing prices and discounts due to volume purchases
e Warehousing and distribution: inventory holding space and costs, shipping
methods and utilizations
With an in-depth understanding of these components and the plant's current cost
structure, approximations of how these costs will change under the condition that only a
single SKU is produced can be made. Interactions between components must also be
considered (for example, a streamlined packaging machinery can result in additional labor
savings beyond the direct labor saved by eliminating extra changeovers and cleanings as
operator efficiency increases as a result of operating fewer types of equipment).
After the model approximating the plant's costs when producing a single SKU is
completed, these costs can be compared with the current actual costs corresponding to a
varied product portfolio. The difference between the annualized costs of a single-SKU plant
and the annualized costs of the multiple-SKU plant is then the aggregated cost of complexity
due to producing a varied product portfolio.
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Figure 8: Top-down complexity cost model approach.
4.2.2 Assumptions
The assumptions underpinning the top-down complexity cost model are critical in
understanding this general approach to understanding complexity at PharmaCo. These
assumptions are detailed below.
4.2.2.1 Model Fundamentals
The model must present information that can be reasonably extended to the entire
network and product portfolio. Consequently, the model is built around a plant that is
representative of the majority of plants at PharmaCo. The primary criteria for this
characteristic were size of the plant, product mix, production volume, margin, and
production cost. Similarly, the single brand and SKU for the analysis is chosen to be
representative of those commonly produced by PharmaCo. The primary criteria for this
characteristic were process complexity, COGS ratio, drug product complexity, labor content,
production volume, and product lifecycle maturity.
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Costs due to
complexity
The current volume, in packs, is held constant. Specifically, the plant currently
produces a given number of product packs across the 1500 SKUs in the current production
portfolio. The single-SKU model is built assuming this same number packs per year.
4.2.2.2 Capital Equipment
Existing capital equipment and machinery currently in the plant are often capable of
producing multiple variations of products. This, logically, is advantageous for a plant that
produces several different SKUs, each with a unique combination of final drug form,
dosage, packaging, and format. For the single-SKU model, existing multi-use capital
equipment currently in the plant is replaced with equipment that may only be capable of
producing a single product configuration if the single configuration is less expensive. This
single configuration equipment is also often capable of higher run-rates. When it is possible
to replace machinery in the plant with less expensive equipment in the single-SKU cost
model, the annualized depreciation savings are subtracted out of the annual cost structure.
Similarly, some equipment is left idle after the plant is streamlined for a single SKU
and potential bottlenecks in the production process shift. In these cases, the depreciation of
the now idle equipment is subtracted out of the cost model.
4.2.2.3 Labor
Direct labor (i.e. operators) is evaluated from the baseline under the current cost
structure. Manufacturing operations are analyzed to quantify setups, changeovers, and
equipment cleanings (required from switching from one drug product to another on the same
production line) that would be eliminated or reduced under a streamlined, single-SKU
scenario. These reductions translate directly to a reduced number of direct labor hours.
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The current multi-SKU production system also often requires producing batch sizes
that are much less than the maximum possible; this is because volume on orders is spread
out across the 1500 SKUs and in only some cases are order sizes large enough to require a
maximum batch size. A single-SKU production plan allows larger batch sizes, which results
in fewer batches being run. This translates directly into fewer required labor hours in the
single-SKU model.
Indirect labor consists of supervisors, material handlers, line managers, and other
support staff. This labor varies proportionally with overall direct labor hours. As a result,
indirect labor was reduced proportionally with the reduction in direct labor hours.
Labor related to product quality can be classified into the two groups. The first,
quality control (QC), consists of quality and production engineers that are responsible for
directly sampling and controlling quality of the product at various stages in the production
process. The number of hours of QC labor required to analyze product is reduced by larger
batch sizes and the fact that there is only one type of drug product in the single-SKU model.
The second category of quality labor, quality assurance (QA), is responsible for overall
compliance to quality regulations. The QA staff are mandated by regulatory agencies and,
therefore, are not reduced in the single-SKU model.
Maintenance staff are considered a fixed cost and are left unadjusted. IT costs are
variable to the number of full-time employees (FTEs) required in the plant after the above
adjustments have been made. Other labor, such as accounting staff and material purchasers,
are adjusted down on a case-by-case basis.
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4.2.2.4 Materials
Several materials in the production process can be reduced in the single-SKU model.
Many of these reductions occur because larger batch sizes and larger lot sizes are run during
the production process. As a result, cost reductions occur because only one type of material
is often needed, resulting in larger bulk discounts when purchasing materials. Also,
reductions occur because of the opportunity to use materials that may be nominally less
expansive. For example, some products utilize folding boxes that are more expensive and
complex than those used for the SKU represented in the single-SKU model. Costs for the
material categories listed below are reduced in the single-SKU model as a result of the
changes to batch sizes and lot sizes. Impacts from other materials are assumed to be
negligible.
* Printed foil
* Leaflets
* Folding boxes
4.2.2.5 Other Assumptions and Adjustments
Almost all consumption of utilities (electricity, gas, and water) is primarily driven by
infrastructure and HVAC. As a result, reductions in the single-SKU model are minimal and
utility costs are left unaltered from the multi-SKU plant. The balance of all other expenses
represents 9% of total expenses. This balance is scaled proportionally to full-time employee
(FTE) labor hours in the single-SKU model.
Figure 9 below summarizes the assumptions and general approach for the top-down
single-SKU model.
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Figure 9: Comparison of single-SKU and multi-SKU cost model assumptions.
4.2.3 Model
Based on the assumptions described above, a plant that is representative of
PharmaCo was selected as a basis for the top-down complexity cost model. Additionally, a
representative SKU and brand were also selected. In order to break the components of the
plant into separate areas to be analyzed, a general process map for the major stages of
processing was developed and can be seen in the Appendix. The assumptions were applied
as explained above.
4.2.4 Results
The top-down cost model revealed a number of key insights into complexity costs at
PharmaCo. From an aggregated level, complexity costs account for 37% of the cost structure
in a representative PharmaCo operation, as shown below in Figure 10.
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Figure 10: Complexity costs derived from top-down model.
Additionally, a proportional breakdown of the specific complexity costs is shown
below in Figure 11. Labor accounts for the largest portion of complexity costs followed by
equipment depreciation.
I Personnel Costs
* Depreciation
Maintenance
*IT Costs
aConsumables and
3rd Party Services
I Taxes
Materials
Figure 11: Complexity cost breakdown (proportional).
The number of batches required to be run are reduced significantly, as shown below
in Figure 12 (data is normalized to a scale of 100). The reduction is particularly large for
packaging, where a drug product from a large single processing batch is divided up into
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several different packaging batches destined for different markets and product configuration
offerings.
Figure 12: Comparison of production batches required (normalized to scale of 100).
A significant portion of the capital equipment and machinery is also required by
offering a complex product portfolio, as shown below in Figure 13. A single-SKU plant
requires less multipurpose machinery, which is typically less expensive (and often capable
of higher run-rates).
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Figure 13: Comparison of required machinery (normalized to scale of 100).
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Labor, which accounts for a significant portion of the cost due to complexity, is
almost halved in a single-SKU scenario, as shown below in Figure 14. The amount of direct
and indirect labor required by complexity is almost twice that of a simple, single-SKU
product portfolio. Larger batch sizes, higher run rates, fewer equipment changeovers, and
fewer equipment cleanings in a single-SKU scenario are the primary drivers of these labor
reductions.
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Figure 14: Comparison of required labor (normalized to scale of 100).
Material costs are shown below in Figure 15. This shows that about one-fifth of
material costs are due to complexity, with the largest portion allocated to leaflets. Larger
bulk buys and fewer unique requirements for a single-SKU scenario are the largest factors
that result in the reductions to material costs in a single-SKU product portfolio.
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Figure 15: Comparison of required material costs (normalized to scale of 100).
Finally, a summary of all non-labor and non-material costs is shown below in Figure
16. Again, this shows that among the expenses that are not directly COGS, depreciation of
equipment that is not required in a single-SKU product portfolio is the largest driver of
complexity cost.
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Figure 16: Comparison of non-labor and non-material costs (normalized to scale of 100).
With these cost models and findings, we will move in the next chapter to a specific
complexity reduction case study at PharmaCo wherein inventory savings are realized by
consolidating SKUs in the product portfolio. This specific case study will provide an
example of the types of savings possible through effective management of complexity in the
product portfolio.
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5 Case Study - Safety Stock Holding Costs
A complex product portfolio typically results in a high number of SKUs that a
company must maintain, produce, and supply. PharmaCo currently maintains a product
portfolio of roughly 15,000 SKUs. The inventory holding costs for such a varied product
portfolio can be significant, particularly for a global company like PharmaCo that produces
and sells a high volume of units across its entire product portfolio. Inventory costs are
further driven by the objective to minimize stockouts for these products.
Inventory holding costs generally consist of costs due to cyclical stock and costs due
to safety stock. Cyclical stock represents inventory that is produced to directly meet order
demand. Safety stock represents inventory that acts is held in reserve as a buffer against
variation in demand so as to ensure that customer orders are filled to a given service level.
Inventory holding costs due to reductions in cyclical stock tend to be fairly straight-
forward calculations. Indeed, PharmaCo has been able to determine the savings due to
reductions in cyclical stock (which are often caused by pruning SKUs from the product
portfolio for a variety of reasons) with general clarity and confidence. Rather, cost savings
due to safety stock reductions will be discussed in this chapter.
5.1 Business Unit SKU Reduction Pilot
As part of the effort to understand and reduce product portfolio complexity at
PharmaCo, pilot programs are being proposed to explore the effects of complexity
management efforts. One such pilot is being implemented in PharmaCo's business unit
located in Country X. The product portfolio currently consists of 454 SKUs. However,
reductions are being made to SKUs corresponding to new product launches, sample packs,
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commercial packs, and hospital packs, as shown below in Figure 17. The effects on holding
costs due to safety stock reductions will be examined here.
500 -
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Figure 17: SKU reduction pilot for Country X business unit
Country X has agreed to eliminate sample packs for new product launches that are
now more than two years into the product lifecycle. Sample packs for new product launches
are intended to introduce potential customers to the new product offering. After a newly
launched product has been on the market for more than two years, it is reasonable to assume
that it has been sufficiently introduced to the market and new launch sample packs are no
longer needed.
The sample packs and commercial packs that have been identified for pruning
typically experience very low and sporadic volumes. Additionally, many of these SKUs are
similar in configuration to other SKUs also currently in the product portfolio. As a result, it
is reasonable to assume that some of the limited volume currently associated the SKUs that
are being eliminated will be transferred to another existing SKU. However, for the purposes
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of this analysis, the more conservative assumption that all volume for a pruned SKU is lost
and not transferred to another SKU will be employed.
In Country X's current product portfolio, a number of products that are nearly
identical in drug form, dosage, and pack configuration are sold through both typical
commercial channels as well as hospitals. Often, the only difference is that the hospital
packs have a slightly different outer packaging (often due to different pricing). As a result,
these identical products are assigned different SKUs depending on the channel through
which they will be sold. In Country X, it has been agreed that 113 SKUs associated with
such hospital packs will be eliminated and the demand will be filled by commercial packs.
Any potential outer packaging differences (which are few) will be addressed through a
simple, low-cost delayed differentiation, such as a sticker that can be applied to the
packaging. As a result, all of the volume from the eliminated hospital packs will be
transferred to the corresponding commercial pack SKUs that remain.
5.2 Approach
Two approaches can be employed to estimate the impact on safety stock holding
costs due to the pilot program described above: one is very simplistic and provides a fast,
first-order approximation; the other is relatively more sophisticated, requires more data, and
typically provides better accuracy.
Holding costs due to safety stock can be calculated as the following [6]:
Safety Stock Holding Costs = r -v -ss
where r is the cost of capital rate, v is the value of each inventory unit, and ss is the safety
stock (in units).
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5.2.1 The Square-root Rule
In an inventory distribution network, reducing the number of stocking points
(typically distribution centers) can result in a reduction of the total amount of safety stock
required to be held [7]. The reduction in safety stock can be calculated according to the
following:
SSc = SSd
where sse is the safety stock in the consolidated system, ssd is the safety stock in the
decentralized system, ne is the number of distribution centers in the consolidated system, and
nd is the number of distribution centers in the decentralized system.
This model can be adapted to approximate the safety stock reduction in the case
where two SKUs are consolidated to one SKU and all of the volume is transferred to the
remaining SKU. In effect, the SKUs become the stocking points in this approximation. A
reduction occurs at the level of individual SKU pairs. Consequently, ne will equal 1 and nd
will equal two for each SKU pair (in every case, two SKUs are being consolidated to one
SKU). As a result, safety stock after consolidating the SKU pairs would be equal to the
original safety stock multiplied by a factor of 1/V2, or roughly a factor of 0.707. In other
words, safety stock in the consolidated scenario would be about 71% of the original safety
stock level, resulting in a 29% reduction in the safety stock. This safety stock reduction of
29% would translate directly into a holding cost savings of 29% for safety stock according
to the equation given above for safety stock holding costs.
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The square-root rule in this form, however, is constrained by a major underlying
assumption: the variability in demand, the variability in forecasting error, and the production
lead times must be equal for both stocking points (or in this case, both SKUs). This is often
not the case. As a result, the square-root rule gives a good back-of-the-envelope estimate for
the upper bound of safety stock holding cost savings possible under these assumptions.
However, a relatively more sophisticated approach is needed for PharmaCo's pilot in
Country X as demand variability, forecasting error variability, and lead times are
significantly different for the two SKUs in each SKU consolidation pair.
5.2.2 Classic Inventory Management Model
Classic single-item inventory management models allow for the impacts of demand
variation and differing product lead times. These models are built on the following
framework and equations [6]. First, the forecast error et is given as
et = xt - Xt
where xt is the actual demand for observation t and ft is the forecasted demand for
observation t.
Next, the root mean squared error (RMSE) is given as
RMSE-
n
where n is the number of observations.
The standard deviation of the forecasting error over the lead time can be expressed as
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I/L
where aL is the standard deviation of errors of forecasts over the lead time, a is the standard
deviation of errors of forecasts for the SKU, L is the lead time, and n is the number of units
of L in each unit of a (for example, if a is given in annual units and L is given in weeks, n
should be given as 52 weeks/year). In this equation, a can be approximated by the RMSE as
calculated by the equation given previously.
Next, the safety stock, ss, can then be calculated as
ss = kaL
where k is derived from a lookup table for c1(k) and c1(k) is the cumulative distribution
function of the unit normal evaluated at k. In practice, a service level SL is typically given or
required (service levels in the pharmaceutical industry are often 99% or higher). This service
level then satisfies the equality
c(k) = SL
This model assumes that the forecasting errors (and the standard deviation of errors of
forecasts) do not vary with total volume of an individual SKU. This is typically not the case
for many inventory systems but is reasonable for our case at PharmaCo.
Finally, in order to combine the demand for two SKUs into one and calculate the
required safety stock in each scenario, an effective a (standard deviation of errors of
forecasts) must be calculated for the consolidated SKU. The two individual a values can be
combined into one according to the following:
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where Ocombined is the new effective standard deviation of errors of forecasts to be used in
the consolidated safety stock calculation, u1 is the standard deviation of errors of forecasts
for the first SKU in the pair, and u 2 is the standard deviation of errors of forecasts for the
second SKU in the pair. This assumes that the correlation of the two SKU distributions is
zero and that they are independent, which are reasonable assumptions in our case.
Utilizing the framework and equations detailed above, the safety stock holding cost
savings for the consolidated hospital packs can be calculated. The general approach to do
this is to first calculate the safety stock (and associated cost) for the two individual SKUs in
each pair. Next, the demand from each eliminated hospital pack is transferred to the
commercial pack that will continue to stay in production and a new effective a can be
calculated for the combined SKU. Finally, the safety stock requirements and associated
costs for the new combined SKU are calculated and compared to the costs in the original
scenario before SKU consolidation. In this way, the savings to safety stock holding costs can
be determined.
5.3 Results
The methods above were applied to the hospital pack SKUs that are being
consolidated into commercial pack SKUs. This SKU consolidation resulted in a 4.6%
reduction to safety stock holding costs, as shown below in Figure 18. PharmaCo is a global
pharmaceutical company, and as such, these safety stock reductions, even in a single country
market, represent a significant cost savings to the company.
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Figure 18: Reduction in safety stock holding costs due to SKU consolidation.
The proportion of safety stock holding costs varies by SKU, as shown below in
Figure 19. This variation is primarily due to the fact that the standard deviation of errors in
forecasts, a, varies significantly across the portfolio as well as across individual SKU pairs.
Additionally, hospital pack SKUs often have longer lead times than the commercial packs.
This is partially driven by the fact that the hospital packs have special packaging layouts and
are often produced less frequently.
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Figure 19: Safety stock holding cost reduction to consolidated SKU pairs.
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6 Conclusion
In this thesis project, we developed an understanding of the key drivers of
complexity for a large company in the pharmaceutical industry. These complexity drivers
can have a significant impact on the overall profitability of the company. These costs drivers
were discovered to be a consequence of the structure of the pharmaceutical industry and of
operating as a global company in the industry.
After defining the complexity drivers, we then developed a model to quantify the
costs due to complexity. A bottom-up complexity cost metric was elusive due to the great
difficulty in defining a standard set of effects that result from introducing a new SKU into
the product portfolio. However, this research yielded other valuable insights into managing
complexity, particularly that complexity originating at the SKU level can be effectively
managed at the plant level through Lean principles. As a result, it is critically important that
well trained Lean experts are included as part of the plant level operations teams.
Next, we utilized a top-down approach to determine the aggregated amount of
complexity costs in a representative PharmaCo production site. While this model lacks
granularity, it provides a very valuable starting point for addressing complexity costs: it was
shown that complexity in the product portfolio drives 37% of costs in the production system.
This is an extremely important piece of information in justifying to upper management that
complexity drives a significant portion of PharmaCo's cost structure and warrants further
resources to better investigate, refine, and manage the complexity.
Finally, we examined a pilot project to consolidate product offerings in the business
unit of Country X. Researching the effects of managing and reducing complexity in the
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product portfolio yielded justification that methods for managing complexity are reasonably
possible to execute. In this case, we showed that the costs due to holding safety stock were
reduced by 4.6% when redundant SKUs are consolidated.
6.1 Next Steps and Further Work
Several opportunities exist to build upon the research and results presented in this
thesis. Foremost, we have established the overall scale of costs due to complexity in the
product portfolio. The next step is to further investigate this aggregated amount of
complexity. It is clear that some of this complexity is unnecessary and suboptimal, but some
of the complexity is good and necessary in order to offer the different products that
customers require. Future work would take the next step into further developing the
complexity cost model and defining the specific components contributing to this complexity.
This could lead to identifying the specific effects on complexity and costs that various
actions related to managing the product portfolio may have.
Additional pilot projects should also be implemented to further examine the
feasibility of actions such as consolidating SKU offerings across a wider range of business
units. These pilot projects could focus on SKU consolidation, SKU and brand pruning, and
SKU creation.
Finally, the interface between operations and marketing plays a key role in how the
product portfolio is shaped. During the course of our research, much information was
gathered regarding the types of tools marketing and brand management staff would
potentially use when managing the product portfolio and launching new products. Further
work could build upon this research and upon the complexity cost models in order to
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develop usable tools to coordinate these functional groups in the business planning process.
This would lead to better and proactive management of complexity in the future.
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Figure 20: Plant granulation, tabletting, and coating layout.
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Diovan 390 bilmin
Un*?
2Shft
2FTE/Shift
HCT 320.190 bUmin
Diovan 320,150 blm n
Una 13
3 Shft
2FTE/Shift
Lescol 250 b/min
Exeft/I 250 bl/min
1 FTE Operational Trnning for al PU Iis
2 OTT(Formador tWc ogias a prtir do Ulhman y Bosch)
Figure 21: Plant packaging layout.
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une 8
3 Shifts
3FTE/Shm
ALU 320 bl/min
PVC 500 b/min
Une 9
3 Shifts
3FTE/Shift
MCT 320 b min
PVC 500 b nin
Una 8 4'T
24 hours
3 FTE
ALU 320 bunin
PVC 500 bI/nin
Figure 22: Packaging line overview.
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